PCN176 COST-EFFECTIVENESS OF SECOND-LINE NILOTINIB VERSUS DASATINIB FOR THE TREATMENT OF PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA-CHRONIC PHASE (PH+ CML-CP) IN ITALY
| Autor: | Maheshwari, V., Tran, D., Agostoni, G., Filioussi, K., Viana, R. |
|---|---|
| Zdroj: | In Value in Health November 2019 22 Supplement 3:S470-S470 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect